AUGTYRO® (repotrectinib): A TREATMENT TARGETING ROS1+ NON-SMALL CELL LUNG OR NTRK+ CANCER

AUGTYRO is a treatment targeting 2 different types of cancer. This treatment option is approved by the FDA to treat ROS1+ non-small cell lung cancer (NSCLC) and NTRK+ cancer. Talk to your healthcare provider to see if AUGTYRO is right for you.

A TREATMENT TARGETED FOR ROS1+ NSCLC

A TREATMENT TARGETED FOR NTRK+ CANCER